Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 10/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496526 | 0.86 | NOTUM (0.59) | CYP46A1AKR1C3PDK2 | |
| SCHEMBL19049632 | 0.83 | TSHR (0.58) | TSHRAKR1C3SLC18A3ADRB1AR | |
| SCHEMBL3436316 | 0.83 | TSHR (0.58) | TSHRAKR1C3SLC18A3ADRB1AR | |
| SCHEMBL16994767 | 0.82 | CYP46A1 (0.52) | CYP46A1TSHR | |
| SCHEMBL3436317 | 0.81 | ALDH1A1 (0.62) | TSHRAKR1C3SLC18A3ADRB1AR | |
| SCHEMBL28242318 | 0.81 | CYP46A1 (0.48) | CYP46A1TSHROPRM1OPRL1PDK2 | |
| SCHEMBL4889125 | 0.80 | NOTUM (0.58) | CYP46A1NPY5RPDK2 | |
| SCHEMBL3436318 | 0.79 | CYP46A1 (0.55) | CYP46A1TSHRNPY5RAKR1C3SLC18A3 | |
| SCHEMBL5806589 | 0.78 | TSHR (0.53) | TSHRNPY5RAKR1C3SLC18A3ADRB1 | |
| SCHEMBL3092123 | 0.78 | TSHR (0.77) | TSHRAKR1C3SLC18A3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CYP46A1 3800/4885TSHR 867/4885OPRM1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.